发布求助
文献互助 智能选刊 最新文献

Klinicka Farmakologie a Farmacie最新文献

筛选
英文 中文
Cost-effectiveness analysis of biological drugs in treating moderate to severe plaque psoriasis from the perspective of a health service provider 从卫生服务提供者的角度分析生物药物治疗中重度斑块型银屑病的成本效益
Klinicka Farmakologie a Farmacie Pub Date : 2022-07-07 DOI: 10.36290/far.2022.010
Jaroslav Duda
{"title":"Cost-effectiveness analysis of biological drugs in treating moderate to severe plaque psoriasis from the perspective of a health service provider","authors":"Jaroslav Duda","doi":"10.36290/far.2022.010","DOIUrl":"https://doi.org/10.36290/far.2022.010","url":null,"abstract":"Republic in 2021, a cost-effectiveness analysis (CEA) was performed for the selected efficacy parameter of PASI 100. The analysis was performed and processed in an interactive way in Excel software into a graphical form, particularly in the form of forest plot graphs (in CER and ICER parameters) and a two-dimensional graph (cost vs. effectiveness) with effectiveness lines being indicated. Results: There are as much as several-fold differences in the cost-effectiveness of individual products according to the CER and ICER parameter values. When taking into account 95% confidence intervals, some differences between the products are even statistically significant. In the case of the most cost-effective sequence of treatment to a gradually more effective drug in a single patient during the induction phase of treatment, induction treatment with a less effective biological drug can be newly initiated, based on such cost savings, in two more patients than when using the second most cost-effective sequence of treatment escalation. Conclusion: A cost-effectiveness analysis (CEA) of biological drugs for the treatment of psoriasis at the level of a health service provider has great potential in the effort to maximize the effectiveness of treatment with limited financial resources or in the effort to provide, with the same limitations, effective treatment to additional patients.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47968753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lanadelumab in hereditary angioedema treatment Lanadelumab用于遗传性血管性水肿治疗
Klinicka Farmakologie a Farmacie Pub Date : 2022-07-07 DOI: 10.36290/far.2022.008
Marta Sobotková
{"title":"Lanadelumab in hereditary angioedema treatment","authors":"Marta Sobotková","doi":"10.36290/far.2022.008","DOIUrl":"https://doi.org/10.36290/far.2022.008","url":null,"abstract":"Hereditární angioedém je vzácné onemocnění, jehož projevem jsou rekurentní angioedémy v různých lokalitách. Nejčastěji bývá podmíněn deficitem C1 inhibitoru. Za hlavní mediátor otoků považujeme u této diagnózy bradykinin. Lanadelumab je plně humánní monoklonální protilátka namířená proti plazmatickému kalikreinu, který z vysokomolekulárního kininogenu bradykinin vyštěpuje. Aktuálně je lanadelumab registrován pro dlouhodobou profylaktickou terapii hereditárního angioedému a představuje velmi účinnou a dobře tolerovanou léčebnou alternativu pro pacienty s častými a závažnými otoky. Klíčová slova: angioedém, bradykinin, lanadelumab.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43648531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventive treatment of migraine in elderly patients, is fremanezumab light at the end of the tunnel? 老年偏头痛患者的预防性治疗，fremanezumab是隧道尽头的光明吗?
Klinicka Farmakologie a Farmacie Pub Date : 2022-07-07 DOI: 10.36290/far.2022.012
Lucia Mokošová
{"title":"Preventive treatment of migraine in elderly patients, is fremanezumab light at the end of the tunnel?","authors":"Lucia Mokošová","doi":"10.36290/far.2022.012","DOIUrl":"https://doi.org/10.36290/far.2022.012","url":null,"abstract":"V kazuistike je prezentovaný prípad polymorbídnej 69-ročnej pacientky s chronickou migrénou, s prakticky nemožnosťou nastavenia na nešpecifickú preventívnu perorálnu liečbu. U pacientky bol náhodne zistený asymptomatický hemangioblastóm v oblasti cerebella vľavo, ktorý bol kompletne resekovaný a napriek výrazným očakávaniam pacientky bez efektu na frekvenciu a intenzitu migrenóznych bolestí hlavy. Po nasadení a pravidelnej mesačnej aplikácii fremanezumabu bola zaznamenaná významná účinnosť a prelomový dopad na kvalitu života pacientky. Kľúčové slová: preventívna liečba, chronická migréna, polymorbidita, fremanezumab.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46184881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determination of ampicillin plasma concentrations in single-dose administration for cardiac surgery prophylaxis 心脏手术预防单剂量给药氨苄西林血药浓度的测定
Klinicka Farmakologie a Farmacie Pub Date : 2022-05-05 DOI: 10.36290/far.2022.001
Vendula Kubíčková, P. Šantavý, K. Urbánek
{"title":"Determination of ampicillin plasma concentrations in single-dose administration for cardiac surgery prophylaxis","authors":"Vendula Kubíčková, P. Šantavý, K. Urbánek","doi":"10.36290/far.2022.001","DOIUrl":"https://doi.org/10.36290/far.2022.001","url":null,"abstract":"Cílem práce bylo stanovit koncentraci ampicilinu v plazmě kardiochirurgických pacientů podstupujících revaskularizaci myokardu bez použití extrakorporálního oběhu a výpočet jeho základních farmakokinetických parametrů. Ke stanovení koncentrace ampicilinu byla zavedena a validována HPLC metoda s UV detekcí a využitím kolony Luna® Omega Polar C18 Column (250 × 4 mm; 5 μm). Individuální farmakokinetické parametry byly vypočteny v programu MW Pharm 3.30 za použití jednokompartmentového modelu. Plazmatické koncentrace ampicilinu byly měřeny u 20 pacientů 15, 30, 45, 60, 120 a 180 min po podání a při ukončení operace. Byla zjištěna průměrná Cmax 127 ± 49 mg/l, poločas eliminace 77 ± 29 min, celková clearance 191 ± 73 ml/min a distribuční objem 19 ± 4 l. Vypočtený průměrný čas, ve kterém plazmatická koncentrace ampicilinu klesla k předpokládané prahové hodnotě účinnosti (1 mg/l), byl 8,5 ± 3,5 h. Klíčová slova: ampicilin, profylaxe, kardiochirurgie, plazmatické koncentrace.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46124888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Physico-chemical properties of colistin and their impact on clinical practice 粘菌素的理化性质及其对临床应用的影响
Klinicka Farmakologie a Farmacie Pub Date : 2022-05-05 DOI: 10.36290/far.2022.006
J. Rychlíčková, Vendula Kubíčková
{"title":"Physico-chemical properties of colistin and their impact on clinical practice","authors":"J. Rychlíčková, Vendula Kubíčková","doi":"10.36290/far.2022.006","DOIUrl":"https://doi.org/10.36290/far.2022.006","url":null,"abstract":"Kolistin je úzkospektré baktericidní antibiotikum ze skupiny lipopeptidů, účinné pouze proti gram-negativním patogenům. Pacientům je podáván ve formě proléčiva – kolistin methansulfonátu, jehož spontánní hydrolýzou dochází k uvolnění vlastního účinného kolistinu. Stabilita kolistin methansulfonátu je závislá na koncentraci, teplotě, pH i složení nosného roztoku. V klinické praxi pak jeho stabilita sehrává roli v případě inhalačního či intravenózního podávání; v případě terapeutického monitorování léčiv je zásadní správné uchovávání vzorků a zvolený typ zkumavek a laboratorních pomůcek. Cílem tohoto přehledového článku je upozornit na jednotlivé rizikové momenty používání kolistinu a jeho terapeutického monitorování. Klíčová slova: kolistin, stabilita, nebulizace, adsorpce, LC-MS.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49055123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Principles of administration of selected medicinal products from the perspective of students' knowledge 从学生知识角度看中药饮片的管理原则
Klinicka Farmakologie a Farmacie Pub Date : 2022-05-05 DOI: 10.36290/far.2022.002
M. Bélová, Martin Krause
{"title":"Principles of administration of selected medicinal products from the perspective of students' knowledge","authors":"M. Bélová, Martin Krause","doi":"10.36290/far.2022.002","DOIUrl":"https://doi.org/10.36290/far.2022.002","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49472551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antifibrinolytics in cardiac surgery 心脏手术中的抗纤溶药物
Klinicka Farmakologie a Farmacie Pub Date : 2022-05-05 DOI: 10.36290/far.2022.005
Roman Hájek
{"title":"Antifibrinolytics in cardiac surgery","authors":"Roman Hájek","doi":"10.36290/far.2022.005","DOIUrl":"https://doi.org/10.36290/far.2022.005","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47113976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of postoperative pain 术后疼痛的治疗
Klinicka Farmakologie a Farmacie Pub Date : 2022-05-05 DOI: 10.36290/far.2022.003
J. Málek
{"title":"Treatment of postoperative pain","authors":"J. Málek","doi":"10.36290/far.2022.003","DOIUrl":"https://doi.org/10.36290/far.2022.003","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48754533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative nausea and vomiting 术后恶心呕吐
Klinicka Farmakologie a Farmacie Pub Date : 2022-05-05 DOI: 10.36290/far.2022.004
M. Frelich, O. Jor, V. Vodička, F. Burša, E. Kušíková
{"title":"Postoperative nausea and vomiting","authors":"M. Frelich, O. Jor, V. Vodička, F. Burša, E. Kušíková","doi":"10.36290/far.2022.004","DOIUrl":"https://doi.org/10.36290/far.2022.004","url":null,"abstract":"Pooperační nauzea a zvracení (PONV) je častou pooperační komplikací, která postihuje 30–50 % pacientů. Nedostatečně léčená PONV zvyšuje perioperační morbiditu (dehiscence operační rány, krvácení, dehydratace), dochází k prodloužení pobytu na dospávacím pokoji i celkové doby hospitalizace. Ondansetron a dexametazon jsou nejčastěji používané látky v prevenci a léčbě PONV. U vysoce rizikových pacientů je indikován multimodální přístup, který spočívá v aplikaci farmakologických a nefarmakologických postupů. Klíčová slova: pooperační nauzea a zvracení, multimodální přístup, ondansetron, dexametazon.","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42830468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antithrombotic therapy in antiphospholipid syndrome, the role of direct oral anticoagulants 抗凝血酶治疗抗磷脂综合征，直接口服抗凝血剂的作用
Klinicka Farmakologie a Farmacie Pub Date : 2022-01-04 DOI: 10.36290/far.2021.024
Jana Hirmerová
{"title":"Antithrombotic therapy in antiphospholipid syndrome, the role of direct oral anticoagulants","authors":"Jana Hirmerová","doi":"10.36290/far.2021.024","DOIUrl":"https://doi.org/10.36290/far.2021.024","url":null,"abstract":"","PeriodicalId":39116,"journal":{"name":"Klinicka Farmakologie a Farmacie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49562371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信